References
- Erenus M, Yucelten D, Durmusoglu F, et al. Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. Fertil Steril 1997; 68: 1000–3
- Fruzzetti F, Bersi C, Parrini D, et al. Treatment of hirsutism: comparisons between different anti-androgens with central and peripheral effects. Fertil Steril 1999; 71: 445–51
- Gregoriou O, Papadias C, Konidaris S, et al. Comparison of flutamide and cyproterone acetate in the treatment of hirsutism: a randomized controlled trial. Gynecol Endocrinol 1996; 10: 119–23
- Dagogo-Jack S, Al-Ali N, Qurttom M. Augmentation of bone mineral density in hirsute women. J Clin Endocrinol Metab 1997; 82: 2821–5
- Prezelj J, Kocijancic A. Comment on spironolactone, but not flutamide administration prevents bone loss in hyperandrogenic women treated with gonadotropin releasing hormone agonist. Horm Metab Res 1994; 26: 46–8
- Rittmaster RS. Medical treatment of androgen dependent hirsutism. J Clin Endocrinol Metab 1995; 80: 2259–63
- Kleerekoper M, Brienza RS, Schultz LR. Oral contraceptive use may protect against low bone mass. Arch Int Med 1991; 151: 1971–6
- Lindsay R, Tohme J, Kanders B. The effect of oral contraceptive use on vertebral bone mass in pre- and post-menopausal women. Contraception 1986; 34: 333–40
- Hreschsyn MM, Hopkins A, Zylstra S. Association of parity, breast feeding and birth control pills with lumbar spine and femoral densities. Am J Obstet Gynecol 1988; 159: 318–22
- Lloyd T, Buchanan JR, Ursino GR, et al. Long-term oral contraceptive use does not affect trabecular bone density. Am J Obstet Gynecol 1989; 160: 402–4
- Castelo-Branco C, Martinez de Osaba Pons E, et al. Effects on bone mass of two oral contraceptives containing ethinylestradiol and cyproterone acetate or desogestrel: results of a 2-year follow-up. Eur J Contracep Reprod Health Care 1998; 3: 79–84
- Watts N, Notelovitz M, Timmons MC, et al. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol 1995; 85: 529–37
- Kasperk C, Fitzsimmons R, Strong D, et al. Studies of the mechanism by which androgens enhance mitogenesis and differentiation in bone cells. J Clin Endocrinol Metab 1990; 71: 1322–9
- Kasperk C, Wergedal J, Farley J, et al. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 1989; 124: 1576–8
- Harrison's Princples of Internal Medicine 13th edn. McGraw-Hill, Inc., London 1994; 2013
- Moghetti P, Castello R, Zamberian N, et al. Spironolactone, but not flutamide administration prevents bone loss in hyperandrogenic women treated with gonadotropin releasing hormone agonist. J Clin Endocrinol Metab 1999; 84: 1250–4